http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2018509457-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N23-20075 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519 |
| filingDate | 2016-03-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-04-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2018509457-A |
| titleOfInvention | Solvated forms of breton-type tyrosine kinase inhibitors |
| abstract | Breton tyrosine kinase (Btk) inhibitor 1-((R) -3- (4-amino-3- (4-phenoxyphenyl) -1H-pyrazolo [3] comprising crystalline form and pharmaceutically acceptable salt thereof , 4-d] pyrimidin-1-yl) piperidin-1-yl) prop-2-en-1-one is described herein. In addition, pharmaceutical compositions containing the solvate and the solvate alone for the treatment of autoimmune diseases or conditions, heterogeneous immune diseases or conditions, cancers including lymphoma, and inflammatory diseases or conditions. Also disclosed are methods of use in combination with other therapeutic agents. [Selection] Figure 1 |
| priorityDate | 2015-03-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1537.